NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $19.89 -0.53 (-2.60%) Closing price 04:00 PM EasternExtended Trading$20.10 +0.21 (+1.06%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ADMA Biologics Stock (NASDAQ:ADMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$19.77▼$20.5350-Day Range$17.86▼$24.5152-Week Range$9.35▼$25.67Volume2.76 million shsAverage Volume3.70 million shsMarket Capitalization$4.75 billionP/E Ratio71.04Dividend YieldN/APrice Target$24.25Consensus RatingBuy Company OverviewADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More… ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreADMA MarketRank™: ADMA Biologics scored higher than 67% of companies evaluated by MarketBeat, and ranked 326th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 2 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth35.29% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 35.29% in the coming year, from $0.51 to $0.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 71.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.74.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 71.04, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 33.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.17% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 6.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.17% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 6.86%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.34 News SentimentADMA Biologics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.02 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for ADMA Biologics this week, compared to 8 articles on an average week.Search Interest46 people have searched for ADMA on MarketBeat in the last 30 days. This is an increase of 84% compared to the previous 30 days.MarketBeat Follows23 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 229% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $182,636.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMA Stock News HeadlinesInsider Selling: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells 1,221 Shares of StockMay 24 at 8:19 AM | insidertrades.com3 Mid-Cap Medical Stocks Outperforming the Market (ADMA)Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.May 6, 2025 | marketbeat.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 27, 2025 | Porter & Company (Ad)Are Options Traders Betting on a Big Move in ADMA Biologics Stock?May 22, 2025 | msn.comDisc Medicine Shows Improved Relative Price Performance; Still Shy Of BenchmarkMay 21, 2025 | msn.comADMA Biologics Reports 40% Increase in 1Q 2025 Revenue, Announces $500 Million Share Repurchase Program and Upgraded Financial GuidanceMay 9, 2025 | nasdaq.comADMA Biologics: Ready For More Growth Despite Q1 Earnings MissMay 9, 2025 | seekingalpha.comADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 8, 2025 | finance.yahoo.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $17.15 on January 1st, 2025. Since then, ADMA stock has increased by 16.0% and is now trading at $19.89. View the best growth stocks for 2025 here. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Wednesday, May, 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by $0.02. The company's quarterly revenue was up 40.2% compared to the same quarter last year. Read the conference call transcript. Who are ADMA Biologics' major shareholders? Top institutional investors of ADMA Biologics include Vanguard Group Inc. (7.09%), Invesco Ltd. (5.42%), Nuveen LLC (1.98%) and American Century Companies Inc. (1.79%). Insiders that own company stock include Steve Elms, Adam S Grossman, Brian Lenz, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade, Lawrence P Guiheen and Bryant Fong. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2025Today5/27/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees530Year FoundedN/APrice Target and Rating Average Stock Price Target$24.25 High Stock Price Target$32.00 Low Stock Price Target$14.00 Potential Upside/Downside+20.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.85 Trailing P/E Ratio71.91 Forward P/E Ratio39.52 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins17.80% Pretax Margin19.16% Return on Equity53.20% Return on Assets26.07% Debt Debt-to-Equity Ratio0.48 Current Ratio7.09 Quick Ratio3.26 Sales & Book Value Annual Sales$459.38 million Price / Sales10.48 Cash Flow$0.06 per share Price / Cash Flow311.70 Book Value$0.60 per share Price / Book33.60Miscellaneous Outstanding Shares238,734,000Free Float227,644,000Market Cap$4.81 billion OptionableOptionable Beta0.57 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ADMA) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.